Incretin hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-13. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
| Property | Value | Notes |
|---|---|---|
| Primary purity method | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Intact mass by LC-MS | Compared with theoretical average mass |
| Sequence verification | Enzymatic peptide mapping | Tandem mass spectrometry of fragments |
| Common degradation route | Deamidation and oxidation | Rate increases with pH and temperature |
| Reference material | Lyophilized peptide standard | Stored desiccated below -20 °C |
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
An extended fatty diacid moiety promotes binding to serum albumin, which slows renal clearance and extends the circulating half-life to roughly five days. That property supports once-weekly administration and largely explains the dosing interval described in clinical reports. Published data come mainly from large randomised programmes that evaluated glycaemic control and body weight over periods of many months. Long-term outcomes beyond those trial windows, including what happens after treatment stops, remain an active area of investigation.
Diabulimia (a portmanteau of diabetes and bulimia), also known as ED-DMT1 (eating disorder-diabetes mellitus type 1) in the US or T1ED (type 1 eating disorder) in the UK, is an eating disorder in which people with type 1 diabetes deliberately give themselves less insulin than they need or stop taking it altogether for the purpose of weight loss. Diabulimia is not recognized as a formal psychiatric diagnosis in the DSM-5. Because of this, some in the medical or psychiatric communities use the phrases "disturbed eating behavior" or "disordered eating behavior" (DEB in both cases) and disordered eating (DE) are quite common in medical and psychiatric literature addressing patients who have type 1 diabetes and manipulate insulin doses to control weight along with exhibiting bulimic behavior. Diabulimia is caused by a range of factors relating to body image, the regular use of insulin, and emotional well-being. Insulin can cause weight gain, and a person who restricts insulin may lose weight. Insulin restriction can lead to the common symptoms of uncontrolled hyperglycemia, which risks complications and a shorter life expectancy. Treatment involves cognitive behavioral therapy, and other support services offered by a multidisciplinary team who work both in diabetes medicine and on eating disorders. Diabulimia is most common in young people, and most of the severe cases tend to occur in women. Research into effective management strategies is ongoing, with a growing medical consensus on the importance of early intervention with specialist teams.
The Albert Einstein College of Medicine is a private medical school in New York City. Founded in 1953, Einstein is an independent degree-granting institution within the Montefiore Einstein Health System. Einstein hosts MD, PhD, and master's programs. Admission to its MD program is highly selective, with an acceptance rate of 1.85% in 2024. Joint masters are offered with the City University of New York and Yeshiva University's Cardozo School of Law. Einstein is also home to one of the first three Medical Scientist Training Programs inaugurated in 1964. This joint MD/PhD program has received continuous funding from the National Institutes of Health. Planning for the college was initiated by Yeshiva University President Samuel Belkin in 1945. Physicist Albert Einstein, who noted that the college would be unique as it would provide medical training to "students of all creeds and races", lent his name to the institution. Due to Yeshiva's financial difficulties, Einstein was transferred to Montefiore in 2015. Following a $1 billion donation to the school by Ruth Gottesman in 2024, Einstein became tuition-free for all MD students. Einstein houses several NIH-designated centers and has contributed to major medical advances, including the first coronary artery bypass surgery. Faculty members have included 18 members of the National Academy of Sciences, three National Medal of Science recipients, and neurologist and writer Oliver Sacks.
=== Biphasic half-life === Many drugs show a biphasic decline in plasma concentration after a dose: a steep distribution phase as drug leaves the central compartment for tissues (α phase), followed by a shallower elimination phase as drug is cleared (β phase). On a semi-log plot the two phases are approximately linear, with slopes α and β, and corresponding half-lives t1/2α = 0.693/α and t1/2β = 0.693/β. For single doses of lipophilic, multi-compartment drugs, clinical duration after onset is often driven by the distribution (α) phase, because by the time distribution equilibrium is reached plasma levels are frequently below any minimal effective concentration, so the terminal β phase has little bearing on observable effects. As a result, classifying drugs by terminal (β) half-life can poorly predict duration of action, whereas α half-life is often more informative—though less commonly reported in labels and reviews. Exceptions exist when elimination is extremely rapid: for very short-acting agents, the β phase can meaningfully shorten effect duration even after a single dose (e.g., triazolam, midazolam). The longer half-life is called the terminal half-life and the half-life of the largest component is called the dominant half-life. For a more detailed description see Pharmacokinetics § Multi-compartmental models.
protons and neutrons have different masses, and different nuclides have different ratios of protons and neutrons. atomic masses are reduced, by the binding energies between the protons and neutrons. The ratio of atomic mass to mass number (number of nucleons) varies from 0.9988381346(51) for 56Fe to 1.007825031898(14) for 1H. Any mass defect due to nuclear binding energy is experimentally a small fraction (less than 1%) of the mass of an equal number of free nucleons. When compared to the average mass per nucleon in carbon-12, which is moderately strongly bound compared with other atoms, the mass defect of binding for most atoms is an even smaller fraction of a dalton. Since free protons and neutrons differ from each other in mass by a small fraction of a dalton (1.38844933(49)×10−3 Da), rounding the relative isotopic mass, or the atomic mass of any given nuclide given in daltons to the nearest whole number, always gives the nucleon count, or mass number. Additionally, the neutron count (neutron number) may then be derived by subtracting the number of protons (atomic number) from the mass number (nucleon count).
Sources: en.wikipedia.org
=== Novo Nordisk === Thomsen joined Novo Nordisk in 1991 as the head of growth hormone research. In 1994, he was appointed senior vice president of diabetes research & development. In November 2000, he became executive vice president and chief scientific officer, overseeing global operations related to drug and device research, chemistry, manufacturing and controls (CMC), global development, medical affairs, regulatory affairs, and safety. During his tenure, more than 20 pharmaceutical products were developed and approved.
Neurologic examination A systematic clinical assessment of motor, sensory, reflex, and cognitive function to diagnose disorders of the nervous system. Neuromodulation The physiological process by which a given neuron uses chemicals to regulate diverse populations of neurons. May be endogenous (e.g., dopamine) or externally applied via electrical stimulation. Neuromodulator A substance that alters the effectiveness of synaptic transmission without directly causing excitatory or inhibitory postsynaptic potentials. Examples include serotonin, acetylcholine, and norepinephrine. Neuron A specialized cell in the nervous system that transmits electrical and chemical signals. Composed of a cell body, axon, and dendrites. Neuropil A dense network of interwoven nerve fibers, dendrites, and glial processes where synaptic activity occurs, commonly found in the gray matter of the brain. Neuroplasticity See neural plasticity. Neuroprosthetics A field that develops devices that interface with the nervous system to restore lost function, such as cochlear implants or brain–computer interfaces. Neuropsychiatry A medical field combining aspects of neurology and psychiatry to treat disorders with both neurological and psychiatric components, such as OCD or Tourette syndrome. Neuropsychology The study of the relationship between brain function and behavior, often using cognitive testing and brain imaging to assess individuals with brain injury or disease.
Elion (1918–1999), American biochemist and recipient of the 1988 Nobel Prize in Physiology or Medicine for innovative methods of rational drug design Conrad Elvehjem (1901–1962), American biochemist who identified two vitamins, nicotinic acid (niacin) and nicotinamide Harry Julius Emeléus (1903–1993), British inorganic chemist known for work on fluorine chemistry Gladys Anderson Emerson (1903–1984), American chemist and early nutritionist, and the first person to isolate Vitamin E Emil Erlenmeyer (1825–1909), German chemist known for the early development of the theory of chemical structure and formulating the Erlenmeyer rule. Richard R. Ernst (1933–2021), Swiss physical chemist, 1991 Nobel Prize in Chemistry for the development of Fourier transform nuclear magnetic resonance spectroscopy Gerhard Ertl (born 1936), German physical chemist who laid the foundation of modern surface chemistry, 2007 Nobel prize in chemistry Margaret C. Etter (1943–1992), American chemist and developer of solid state chemistry for crystalline organic compounds Hans von Euler-Chelpin (1873–1964), Swedish chemist, winner of the 1929 Nobel Prize in Chemistry for work on the fermentation of sugar and enzymes Henry Eyring (1901–1981), Mexico-born American theoretical chemist known for the absolute rate theory of chemical reactions
Pulmonary fibrosis is typically a condition in which the lungs become scarred over time. Symptoms include shortness of breath, a dry cough, feeling tired, weight loss, and nail clubbing. Complications may include pulmonary hypertension, respiratory failure, pneumothorax, and lung cancer. Causes include environmental pollution, certain medications, connective tissue diseases, infections, and interstitial lung diseases. But in most cases the cause is unknown (idiopathic pulmonary fibrosis). Diagnosis may be based on symptoms, medical imaging, lung biopsy, and lung function tests. No cure exists and treatment options are limited. Treatment is directed toward improving symptoms and may include oxygen therapy and pulmonary rehabilitation. Certain medications may slow the scarring. Lung transplantation may be an option. At least 5 million people are affected globally. Life expectancy is generally less than five years following diagnosis.
As the membrane potential is increased, sodium ion channels open, allowing the entry of sodium ions into the cell. This is followed by the opening of potassium ion channels that permit the exit of potassium ions from the cell. The inward flow of sodium ions increases the concentration of positively charged cations in the cell and causes depolarization, where the potential of the cell is higher than the cell's resting potential. The sodium channels close at the peak of the action potential, while potassium continues to leave the cell. The efflux of potassium ions decreases the membrane potential or hyperpolarizes the cell. For small voltage increases from rest, the potassium current exceeds the sodium current and the voltage returns to its normal resting value, typically −70 mV. However, if the voltage increases past a critical threshold, typically 15 mV higher than the resting value, the sodium current dominates. This results in a runaway condition whereby the positive feedback from the sodium current activates even more sodium channels. Thus, the cell fires, producing an action potential. The frequency at which a neuron elicits action potentials is often referred to as a firing rate or neural firing rate. Currents produced by the opening of voltage-gated channels in the course of an action potential are typically significantly larger than the initial stimulating current. Thus, the amplitude, duration, and shape of the action potential are determined largely by the properties of the excitable membrane and not the amplitude or duration of the stimulus.
Sources: en.wikipedia.org
The tunicates have three distinct adult shapes. Each is a member of one of three monophyletic clades. All tunicate larvae have the standard chordate features, including long, tadpole-like tails. Their larva also have rudimentary brains, light sensors and tilt sensors. The smallest of the three groups of tunicates is the Appendicularia. They retain tadpole-like shapes and active swimming all their lives, and were for a long time regarded as larvae of the other two groups. The other two groups, the sea squirts and the salps, lose the notochord, the nerve cord, and the post-anal tail as they metamorphize into adult forms. Both are soft-bodied filter feeders with multiple gill slits, and feed on plankton. Sea squirts are sessile organisms and consist mainly of water pumps and filter-feeding apparatus. Most attach firmly to the sea floor, where they remain in one place for life. The salps float in mid-water and have a two-generation cycle in which one generation is solitary and the next forms chain-like colonies. The etymology of the term Urochordata (Balfour 1881) is from the ancient Greek οὐρά (oura, "tail") + Latin chorda ("cord"), because the notochord is only found in the tail. The term Tunicata (Lamarck 1816) is recognised as having precedence and is now more commonly used.
=== Impact of Coronavirus and CARES Act of 2020 === The COVID-19 pandemic in the United States impacted the economy significantly beginning in March 2020, as businesses were shut-down and furloughed or fired personnel. About 16 million persons filed for unemployment insurance in the three weeks ending April 9. It caused the number of unemployed persons to increase significantly, which is expected to reduce tax revenues while increasing automatic stabilizer spending for unemployment insurance and nutritional support. As a result of the adverse economic impact, both state and federal budget deficits will dramatically increase, even before considering any new legislation. To help address lost income for millions of workers and assist businesses, Congress and President Trump enacted the Coronavirus Aid, Relief, and Economic Security Act (CARES) on March 18, 2020. It included loans and grants for businesses, along with direct payments to individuals and additional funding for unemployment insurance. Some or all of the loans may ultimately be paid back including interest, while the spending measures should dampen the negative budgetary impact of the economic disruption. While the law will almost certainly increase budget deficits relative to the January 2020 10-year CBO baseline (completed prior to the Coronavirus), in the absence of the legislation, a complete economic collapse could have occurred. CBO provided a preliminary score for the CARES Act on April 16, 2020, estimating that it would increase federal deficits by about $1.8 trillion over the 2020-2030 period.
After hypothyroidism was found to cause a lower basal metabolic rate, this was used as a marker to guide adjustments in therapy in the early 20th century (around 1915). However, a low basal metabolic rate was known to be non-specific, also present in malnutrition. The first laboratory test to help assess thyroid status was the serum protein-bound iodine, which came into use around the 1950s. In 1971, the thyroid stimulating hormone (TSH) radioimmunoassay was developed, which was the most specific marker for assessing thyroid status in patients. Many people who were being treated based on basal metabolic rate, minimizing hypothyroid symptoms, or based on serum protein-bound iodine, were found to have excessive thyroid hormone. The following year, in 1972, a T3 radioimmunoassay was developed, and in 1974, a T4 radioimmunoassay was developed.
== Taxonomy == The death cap is named in Latin as such in the correspondence between the English physician Thomas Browne and Christopher Merrett. It was described by French botanist Sébastien Vaillant in 1727, who gave a succinct phrase name "Fungus phalloides, annulatus, sordide virescens, et patulus" (a phallus-shaped, ring-stemmed, dirty green mushroom with a large 'spreading' cap). In 1821, Elias Magnus Fries described it as Agaricus phalloides, but included all white amanitas within its description. Finally, in 1833, Johann Heinrich Friedrich Link settled on the name Amanita phalloides, after Persoon had named it Amanita viridis 30 years earlier. Although Louis Secretan's use of the name A. phalloides predates Link's, it has been rejected for nomenclatural purposes because Secretan's works did not use binomial nomenclature consistently; some taxonomists have, however, disagreed with this opinion. Amanita phalloides is the type species of Amanita section Phalloideae, a group that contains all of the deadly poisonous Amanita species thus far identified. Most notable of these are the species known as destroying angels, including A. virosa, A. bisporigera, A. ocreata, A. verna, and more than a dozen others. The term "destroying angel" has been applied to A. phalloides at times, but "death cap" is by far the most common vernacular name used in English. Other common names also listed include "stinking amanita" and "deadly amanita". A rarely appearing, all-white form was initially described A. phalloides f. alba by Max Britzelmayr, though its status has been unclear.
Sources: en.wikipedia.org
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.
Higher pH and elevated temperature both increase deamidation rates. Holding solutions at low temperature and near-neutral to slightly acidic pH reduces the extent of the reaction.
Removing water slows hydrolysis and aggregation. The dry powder tolerates longer storage intervals than a solution kept at the same temperature.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.